Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content
Fig. 2 | BMC Immunology

Fig. 2

From: TLR7 agonist, DSP-0509, with radiation combination therapy enhances anti-tumor activity and modulates T cell dependent immune activation

Fig. 2

Dosing schedule affected the systemic DSP-0509-enhanced anti-tumor activity of RT in the 4T1 model. (A) Study schedule for RT combined with DSP-0509 in the CT26 model. (B) Anti-tumor activity in CT26 cells with different dosing schedules of DSP-0509. n = 10 / group and **P < 0.01 by the Dunnett test. (C) Kaplan-Meier curve of the data in Fig. 2B. *P < 0.05 Log-rank test vs. q2w group. (D) The 4T1 tumor growth curve. DSP-0509 was administered at 5 mg/kg once a week intravenously. Radiation was dosed at 2 Gy/day for five sequential days from the starting day of DSP-0509 dosing. **P < 0.01, *P < 0.05 for the Tukey test. n = 8 / group and the values are the mean and SEM (error bar)

Back to article page

BMC Immunology

ISSN: 1471-2172

Contact us